Korea Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 5,
"returned": 5,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "9916baea-24e0-47f2-9abb-cbd2f01e3d3a",
"title": "Heavy Construction Equipment Market Surges to USD 253.52 Billion by 2031, Propelled by 6.81% CAGR - Verified Market Research®",
"description": "The heavy construction equipment market is driven by rapid urbanization, increasing infrastructure development, and technological advancements in...",
"keywords": "Verified Market Research, Heavy Construction Equipment, Construction Equipment Market, infrastructure development, public infrastructure, Market Research",
"snippet": "Lewes, Delaware, July 26, 2024 (GLOBE NEWSWIRE) -- The Global Heavy Construction Equipment Market Size is projected to grow at a CAGR of 6.81% from 2024 to 2031...",
"url": "https://www.globenewswire.com/news-release/2024/07/26/2919647/0/en/Heavy-Construction-Equipment-Market-Surges-to-USD-253-52-Billion-by-2031-Propelled-by-6-81-CAGR-Verified-Market-Research.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/707830b6-cf87-43db-be66-c125971e42be",
"language": "en",
"published_at": "2024-07-26T14:00:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "267270.KS",
"name": "Hyundai Construction Equipment Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Industrials",
"match_score": 45.411877,
"sentiment_score": 0.311325,
"highlights": [
{
"highlight": "rid=39328\n\nBrowse in-depth TOC on “Global Heavy Construction Equipment Market Size”\n\n202 - Pages\n\n126 – Tables\n\n37 – Figures\n\nScope Of The Report\n\nREPORT ATTRIBUTES DETAILS STUDY PERIOD 2021-2031 BASE YEAR 2024 FORECAST PERIOD 2024-2031 HISTORICAL PERIOD 2021-2023 UNIT Value (USD Billion) KEY COMPANIES PROFILED Deere & Company, <em>Hyundai</em> <em>Construction</em>",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Equipment</em> <em>Co</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Ltd</em>., SANY Group, Terex Corporation, JCB, AB Volvo, CNH Industrial. SEGMENTS COVERED • By Type\n\n• By Application\n\n• By Geography CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analysts’ working days) with purchase. Addition or alteration to country, regional & segment scope.",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "Heavy Construction Equipment Market Key Players Shaping the Future\n\nMajor players, including Deere & Company, <em>Hyundai</em> <em>Construction</em> <em>Equipment</em> <em>Co</em>. <em>Ltd</em>., SANY Group, Terex Corporation, JCB, AB Volvo, CNH Industrial. and more, play a pivotal role in shaping the future of the Heavy Construction Equipment Market.",
"sentiment": 0.3947,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "1094837d-9160-4834-8ebe-e93acd3de578",
"title": "CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior ther",
"description": "Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options...",
"keywords": "Janssen EMEA",
"snippet": "Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after...",
"url": "https://www.globenewswire.com/news-release/2024/07/26/2919538/0/en/CHMP-recommends-RYBREVANT-amivantamab-in-combination-with-chemotherapy-for-the-treatment-of-adult-patients-with-advanced-EGFR-mutated-non-small-cell-lung-cancer-NSCLC-after-failure.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/85723da3-163a-4a4d-bb36-0e46ec3998e6",
"language": "en",
"published_at": "2024-07-26T12:08:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "000105.KS",
"name": "Yuhan Corporation",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.075388,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "., entered into a license and collaboration agreement with <em>Yuhan</em> <em>Corporation</em> for the development of lazertinib.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "000100.KS",
"name": "Yuhan Corporation",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Healthcare",
"match_score": 10.075388,
"sentiment_score": 0.4939,
"highlights": [
{
"highlight": "., entered into a license and collaboration agreement with <em>Yuhan</em> <em>Corporation</em> for the development of lazertinib.",
"sentiment": 0.4939,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "fc0c274a-7f72-4178-9a42-8c3967f2c00e",
"title": "HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update",
"description": "HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agreement for Epigenetic Reprogramming of Aging (ERATM) technology, targeting ophthalmic and otic diseases. Progress in clinical development programs continued including the completion of Phase 1 study for HL192 (ATH-399A) in Parkinson's Disease, with results expected in the second half of 2024 and initiation of VELOS-4 Phase 3 study on tanfanercept for Dry Eye Disease. ROCKVILLE, Md. and SEOUL, South Korea, July 26, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter of 2024 and provided business updates.",
"keywords": "HanAll, Biopharma, Reports, Q2, 2024, Financial, Results, and, Provides, Business, Update",
"snippet": "HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW , driven by the strong sales from the key products.\n\n, driven ...",
"url": "https://www.manilatimes.net/2024/07/26/public-square/pr-newswire/hanall-biopharma-reports-q2-2024-financial-results-and-provides-business-update/1960045",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2024/07/26/380027.jpg",
"language": "en",
"published_at": "2024-07-26T11:29:26.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "009420.KS",
"name": "Hanall Biopharma Co.,Ltd",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Healthcare",
"match_score": 80.122986,
"sentiment_score": 0.183025,
"highlights": [
{
"highlight": "ROCKVILLE, Md. and SEOUL, South Korea\n\nJuly 26, 2024\n\n/PRNewswire/ -- <em>HanAll</em> <em>Biopharma</em> <em>Co</em>., <em>Ltd</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>KRX</em>: <em>009420</em>.<em>KS</em>), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the second quarter of 2024 and provided business updates.\n\n31.6 billion KRW\n\n3.1 billion KRW\n\n28.1 billion KRW\n\nHanAll ended the second quarter with total revenue ofand an operating loss of.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "CONSOLIDATED) Advertisement Key Highlights (KRW in billion) Q2 2024 Q2 2023 % change Sales 31.6 41.4 -23.7 % Gross Profit 15.9 27.2 -41.6 % Selling, marketing and administrative expenses 12.6 11.3 +11.2 % Research and development expenses 6.4 7.8 -18.0 % Operating income (3.1) 8.1 N/A Net Income (3.3) 7.3 N/A\n\nAbout HanAll Biopharma\n\nHanAll Biopharma (<em>KRX</em>",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": ": <em>009420</em>.<em>KS</em>) is a global biopharmaceutical company with presence in Korea, the USA, Japan, and Indonesia with the mission of making meaningful contributions to patients' lives by introducing innovative, impactful medicines to address severe unmet medical needs.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "d7038c90-5037-4858-8e3d-519cb0b44512",
"title": "Singapore stocks dip as forecast after MAS maintains monetary policy; STI down 0.1%",
"description": "The STI fell 3.98 points to 3,426.47. Read more at straitstimes.com.",
"keywords": "",
"snippet": "SINGAPORE - Shares in Singapore ended slightly lower on July 26, after Singapore’s central bank left its monetary policy settings unchanged for the fifth stra...",
"url": "https://www.straitstimes.com/business/companies-markets/singapore-stocks-dip-as-forecast-after-mas-maintains-monetary-policy-sti-down-01",
"image_url": "https://static1.straitstimes.com.sg/s3fs-public/styles/large30x20/public/articles/2024/07/26/IMG42052028129.JPG?VersionId=7SQrOuioczrp3gBhYJhn_EOufTXLsRz3",
"language": "en",
"published_at": "2024-07-26T10:55:00.000000Z",
"source": "straitstimes.com",
"relevance_score": null,
"entities": [
{
"symbol": "^KS11",
"name": "KOSPI Composite Index",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "index",
"industry": "N/A",
"match_score": 41.246727,
"sentiment_score": 0.3818,
"highlights": [
{
"highlight": "Meanwhile, the Hang Seng Index rose 0.1 per cent, and the <em>Kospi</em> <em>Composite</em> <em>Index</em> gained 0.8 per cent. THE BUSINESS TIMES",
"sentiment": 0.3818,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "90ebf63e-f8f8-4719-b7e0-221ee3628834",
"title": "Soal MIP Batu Bara, ESDM: Sudah Dekat & Diparaf Semua Pihak!",
"description": "Kementerian ESDM memastikan Mitra Instansi Pengelola (MIP) batu bara sudah dekat dan sudah diparaf semua pihak",
"keywords": "mitra instansi pengelola, mip, batu bara, mip batu bara, kementerian esdm",
"snippet": "Jakarta, CNBC Indonesia - Kementerian Energi dan Sumber Daya Mineral (ESDM) terang-terangan soal pembentukan Mitra Instansi Pengelola (MIP). Kabar terbarunya, M...",
"url": "https://www.cnbcindonesia.com/news/20240726161139-4-557961/soal-mip-batu-bara-esdm-sudah-dekat-diparaf-semua-pihak",
"image_url": "https://awsimages.detik.net.id/visual/2024/07/26/sejumlah-perahu-tongkang-batu-bara-melintas-di-sungai-mahakam-kota-samarinda-kalimantan-timur-rabu-2472024-sungai-mahakam-berf-1_169.jpeg?w=650",
"language": "id",
"published_at": "2024-07-26T10:20:00.000000Z",
"source": "cnbcindonesia.com",
"relevance_score": null,
"entities": [
{
"symbol": "035720.KS",
"name": "Kakao Corp.",
"exchange": null,
"exchange_long": null,
"country": "kr",
"type": "equity",
"industry": "Communication Services",
"match_score": 24.827106,
"sentiment_score": null,
"highlights": [
{
"highlight": "Saksikan video di bawah ini: Warga RI Tak Perlu Lapor SPT Lagi Hingga Pendiri <em>Kakao</em> <em>Corp</em> Ditangkap",
"sentiment": -0.2263,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "kr",
"total_documents": 6,
"sentiment_avg": 0.372790002822876
}
]
}
Other details
Entity count
- 4,820